Always take this medicine exactly as described in this leaflet or as your doctor or pharmacist has told you.
DEXKETOPROFEN PENSAVITAL is a painkiller from the group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs).
It is used to treat mild to moderate pain, such as muscular pain, painful periods (dysmenorrhoea), toothache.
Do not take DEXKETOPROFEN PENSAVITAL:
Warnings and precautions:
Talk to your doctor or pharmacist before taking DEXKETOPROFEN PENSAVITAL
Children and adolescents
DEXKETOPROFEN PENSAVITAL has not been studied in children and adolescents. Therefore, safety and efficacy have not been established and the product should not be used in children and adolescents.
Other medicines and DEXKETOPROFEN PENSAVITAL
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription. There are some medicines that should not be taken together and others that may need their doses to be altered when taken together.
Always inform your doctor, dentist or pharmacist if you are using or receiving any of the following medicines in addition to DEXKETOPROFEN PENSAVITAL:
Inadvisable combinations:
Combinations requiring precautions:
Associations to be considered carefully:
If you have any doubts about taking other medicines with DEXKETOPROFEN PENSAVITAL, consult your doctor or pharmacist.
DEXKETOPROFEN PENSAVITAL with food and drink
Take the tablets with an adequate amount of water. Take your tablets with food, as it helps to decrease the risk of stomach or bowel side effects. However, if you have acute pain, take the tablets on an empty stomach, i.e. at least 30 minutes before meals, as this helps the medicine start working a little faster.
Pregnancy, breastfeeding and fertility
Do not take DEXKETOPROFEN PENSAVITAL if you are in the final 3 months of pregnancy as it could harm your unborn child or cause problems at delivery. It can cause kidney and heart problems in your unborn baby. It may affect your and your baby’s tendency to bleed and cause labour to be later or longer than expected. You should not take DEXKETOPROFEN PENSAVITAL during the first 6 months of pregnancy unless absolutely necessary and advised by your doctor. If you need treatment during this period or while you are trying to get pregnant, the lowest dose for the shortest time possible should be used. If taken for more than a few days from 20 weeks of pregnancy onward, DEXKETOPROFEN PENSAVITAL can cause kidney problems in your unborn baby that may lead to low levels of amniotic fluid that surrounds the baby (oligohydramnios) or narrowing of a blood vessel (ductus arteriosus) in the baby’s heart. If you need treatment for longer than a few days, your doctor may recommend additional monitoring.
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine as DEXKETOPROFEN PENSAVITAL may not be suitable for you.
The use of DEXKETOPROFEN PENSAVITAL should be avoided by women planning to have a baby or who are pregnant. Treatment at any time during pregnancy should only take place as instructed by a doctor.
The use of DEXKETOPROFEN PENSAVITAL is not recommended while attempting to conceive or during investigation of infertility.
Driving and using machines
DEXKETOPROFEN PENSAVITAL may slightly affect your ability to drive and handle machines, due to the possibility of dizziness or drowsiness as side effects of treatment. If you notice such effects, do not drive or use machines until the symptoms wear off. Ask your doctor for advice.
DEXKETOPROFEN PENSAVITAL contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per tablet; this means that it is essentially “sodium free”.
Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.
The dose of DEXKETOPROFEN PENSAVITAL that you need depends on the type, severity and duration of your pain. Your doctor will tell you how many tablets you must take daily, and for how long.
The recommended dose is generally 1 tablet (25 mg) every 8 hours with no more than 3 tablets daily (75 mg).
If you are elderly, or if you suffer from kidney or liver problems, you should start treatment with a total daily dose of no more than 2 tablets (50 mg).
In elderly patients this initial dose can later be increased to that generally recommended (75 mg) if DEXKETOPROFEN PENSAVITAL has been well tolerated.
If your pain is intense and you need quicker relief, take the tablets on an empty stomach (at least 30 minutes before food) because they will be more easily absorbed (see section 2 “DEXKETOPROFEN PENSAVITAL with food and drink”).
Use in children and adolescents
This medicine should not be used in children and adolescents (under 18 years old).
If you take more DEXKETOPROFEN PENSAVITAL than you should
If you take too much of this medicine, tell your doctor or pharmacist immediately or go to the emergency department of your nearest hospital. Please remember to take this medicine pack or this leaflet with you.
If you forget to take DEXKETOPROFEN PENSAVITAL
Do not take a double dose to make up for a forgotten tablet. Take the next regular dose when it is due (according to section 3 “How to take DEXKETOPROFEN PENSAVITAL”).
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Possible side effects are listed below according to how likely they are to occur.
Common side effects (may affect up to 1 in 10 people):
Nausea and/or vomiting, stomach ache, diarrhoea, digestive problems (dyspepsia).
Uncommon side effects (may affect up to 1 in 100 people):
Spinning sensation (vertigo), dizziness, sleepiness, disturbed sleep, nervousness, headache, palpitations, flushing, stomach problems, constipation, dry mouth, flatulence, skin rash, tiredness, pain, feeling feverish and shivering, generally feeling unwell (malaise).
Rare side effects (may affect up to 1 in 1,000 people):
Peptic ulcer, peptic ulcer perforation or bleeding (which may be seen as vomiting blood or black stools), fainting, high blood pressure, too-slow breathing, water retention and peripheral swelling (e.g. swollen ankles), laryngeal oedema, loss of appetite (anorexia), abnormal sensation, itchy rash, acne, increased sweating, back pain, passing water frequently, menstrual disorders, prostate problems, abnormal liver function tests (blood tests), liver cell injury (hepatitis), acute renal failure.
Very rare (may affect up to 1 in 10,000 people):
Anaphylactic reaction (hypersensitive reaction which may also lead to collapse), open sores on skin, mouth, eyes and genital areas (Stevens Johnson and Lyell’s syndromes), face swelling or swelling of the lips and throat (angioedema), breathlessness due to narrowing of the airways (bronchospasm), shortness of breath, fast heartbeat, low blood pressure, inflammation of the pancreas, blurred vision, ringing in the ears (tinnitus), sensitive skin, sensitivity to light, itching, kidney problems. Reduced white blood cell count (neutropenia), fewer platelets in the blood (thrombocytopenia).
Tell your doctor immediately if you notice any stomach/bowel side effects at the start of treatment (e.g. stomach pain, heartburn or bleeding) and especially if you are elderly.
Stop using DEXKETOPROFEN PENSAVITAL as soon as you notice the appearance of a skin rash, or any lesion inside the mouth or on the genitals, or any sign of an allergy.
During treatment with non-steroidal anti-inflammatory drugs, fluid retention and swelling (especially in the ankles and legs), increased blood pressure and heart failure have been reported.
Medicines such as DEXKETOPROFEN PENSAVITAL may be associated with a small increased risk of heart attack («myocardial infarction») or stroke.
In patients with immune system disorders that affect connective tissue (systemic lupus erythematosus or mixed connective tissue disease), anti-inflammatory medicines may rarely cause fever, headache and neck stiffness.
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system at https://www.aifa.gov.it/content/segnalazioni-reazioni-avverse
Reporting side effects contributes to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the box and on the blister. The expiry date refers to the last day of the month.
Do not store above 30 °C. Keep the blister packs in the outer carton in order to protect from light.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
What DEXKETOPROFEN PENSAVITAL contains
The active substance is dexketoprofen trometamol (36.90 mg), corresponding to 25 mg of dexketoprofen.
The other ingredients are maize starch, microcrystalline cellulose, sodium starch glycollate, glycerol distearate, hypromellose, titanium dioxide and macrogol 400.
What DEXKETOPROFEN PENSAVITAL looks like and contents of the pack
DEXKETOPROFEN PENSAVITAL is available in the form of white cylindrical, scored tablets with convex sides, with DT2 printed on one side. The tablet can be divided into equal doses.
DEXKETOPROFEN PENSAVITAL is supplied in packs containing 10 or 20 film-coated tablets.
Not all pack sizes may be marketed
Marketing authorisation holder and manufacturer
Marketing Authorisation Holder:
TOWA PHARMACEUITCAL S.p.A.
Via Enrico Tazzoli, 6
20154 Milan – Italy
Manufacturer:
SAG Manufacturing, S.L.U
Crta. N-I, Km 36,
San Agustín de Guadalix,
Madrid, 28750 – Spain
Galenicum Health, S.L.U.
San Gabriel, 50
Esplugues de Llobregat
Barcelona, 08950 – Spain
This medicine is authorised in the Member States of the EEA with the following names:
Portugal: DEXCETOPROFENO PENSAVITAL
Spain: DEXKETOPROFENO PENSAVITAL
Italy: DEXKETOPROFENE PENSAVITAL
This leaflet was last revised in 11/2023